Skip to main content
MS-DRG 848 · MDC 17 · Medical

MS-DRG 848: Chemotherapy without Acute Leukemia as Secondary Diagnosis without CC/MCC

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: IPPS Table 5 (MS-DRG weights): v44 FY2027 (final rule + CN3) (effective October 1, 2026); MS-DRG Definitions Manual: v44 (effective October 1, 2026). Next CMS release: FY2028 final rule (August 2027), effective October 1, 2027; an April 1 interim grouper update when CMS issues one for the IPPS Table 5 (MS-DRG weights); the FY2028 grouper, effective October 1, 2027 for the MS-DRG Definitions Manual.

Key facts for DRG 848

FY2027 relative weight
0.7756
Higher than 10% of all MS-DRGs
Change vs FY2026
-8.7%
FY2026 weight 0.8494
Geometric mean LOS
2.6 days
Arithmetic mean 3.0 days
MDC
17
Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
Severity level
without CC or MCC
National unadjusted operating payment
$5,311.31
Weight × $6,848.00 FY2027 standardized amount; capital adds $418.79
Transfer policy
Not a transfer DRG

TL;DR

MS-DRG 848 is a medical group in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), at the lowest of three severity levels in its family. CMS assigns it a FY2027 relative weight of 0.7756 with a geometric mean length of stay of 2.6 days and an arithmetic mean of 3.0. Its weight moved down 8.7% from FY2026 (0.8494). That weight is higher than 10% of all MS-DRGs. Its weight sits 69.3% below DRG 846 (with MCC, 2.5302) and 42.5% below DRG 847 (with CC, 1.3490). The v44 Definitions Manual assigns it through 3 principal diagnosis codes.

What changed from FY2026 to FY2027

CMS recalibrates every MS-DRG weight annually from the prior year's MedPAR claims. For DRG 848 the FY2027 relative weight is 0.7756 against 0.8494 in FY2026, a fall of 8.69%, which exceeds the 2% threshold worth re-checking in contract models.

FY2026 versus FY2027 payment factors for MS-DRG 848
MetricFY2026FY2027Change
Relative weight0.84940.7756-0.0738
Geometric mean LOS (days)2.62.6+0.0
Arithmetic mean LOS (days)3.33.0-0.3
Weights shown are the FY2027 final values after the 10% cap on year-over-year reductions where applicable.

CC and MCC family

DRG 848 shares its base definition with 2 other MS-DRGs split by severity. The family's weights span 0.7756 to 2.5302, a 3.26× spread, which is the payment effect of documenting qualifying complications and comorbidities.

MS-DRGs in the same base group as DRG 848
DRGTitleFY2027 weightGMLOSNational operating payment
846Chemotherapy without Acute Leukemia as Secondary Diagnosis with MCC2.53025.6$17,326.81
847Chemotherapy without Acute Leukemia as Secondary Diagnosis with CC1.34903.7$9,237.95
848Chemotherapy without Acute Leukemia as Secondary Diagnosis without CC/MCC0.77562.6$5,311.31

At the national rate, documenting the family's top severity level (DRG 846, $17,326.81) instead of its base level (DRG 848, $5,311.31) changes the operating payment by $12,015.50, the amount at stake when a qualifying secondary diagnosis goes undocumented. The figures are national operating amounts before the hospital-specific adjustments described below.

National unadjusted payment for DRG 848

Multiplying the FY2027 relative weight (0.7756) by the national rates in IPPS Tables 1A and 1D, as corrected by notice CMS-1849-CN3, gives the base amounts below. Across the CC/MCC family the operating amount spans $12,015.50.

FY2027 national unadjusted IPPS payment for MS-DRG 848
ComponentNational rateDRG 848
Operating (labor and nonlabor share)$4,519.68 + $2,328.32 = $6,848.00$5,311.31
Capital (federal rate)$539.95$418.79
Operating plus capital$5,730.10
Assumes the full annual update (the hospital submitted quality data and is a meaningful EHR user). A hospital with a reduced update starts from $5,145.17 to $5,269.78 for the operating portion of this DRG.

These are national, unadjusted figures, not what a given hospital is paid. The labor share is multiplied by the hospital's wage index (Table 1A applies when the wage index is above 1.0 and Table 1B otherwise), and teaching (IME), disproportionate share (DSH), outlier, transfer and new-technology add-on rules then change the amount for each stay. Use the figures to compare groups and to size a documentation finding, not to forecast a remittance; the DRG payment calculator applies a hospital's own wage index and teaching and DSH factors to DRG 848.

Grouper logic (v44 Definitions Manual)

The manual's split table for Chemotherapy without Acute Leukemia As Secondary Diagnosis gives one row per combination of criteria and the MS-DRG it assigns. DRG 848 is the row where MCC is No, CC is No.

Split table for Chemotherapy without Acute Leukemia As Secondary Diagnosis
MCCCCDRG
Yesnot checked846
NoYes847
NoNo848

Principal Diagnosis: 3 ICD-10-CM codes in this DRG's assignment logic.

Principal Diagnosis codes in the logic for DRG 848 (sample)
ICD-10-CM codeDescription
Z08Encounter for follow-up examination after completed treatment for malignant neoplasm
Z51.11Encounter for antineoplastic chemotherapy
Z51.12Encounter for antineoplastic immunotherapy

Code editor, HAC and CC/MCC exclusion notes for DRG 848

Because this family splits by CC and MCC, a secondary diagnosis on the hospital-acquired condition list that is reported with a present-on-admission indicator of N or U does not count toward the severity level, and a CC or MCC excluded by the principal diagnosis does not count either. Check a secondary diagnosis and its CC exclusion before relying on it for the higher member.

The Definitions Manual lists the diagnosis and procedure codes that lead to DRG 848; these are the ones that are also on a Medicare Code Editor list and can draw that edit.

Medicare Code Editor v44 lists that include codes in the logic of DRG 848
MCE editListCodesExamples
Edit 9unacceptable principal diagnosis1Z08

Documentation and denial exposure

As a medical DRG, assignment depends on the principal diagnosis sequenced from the attending's documentation; a secondary condition sequenced first, or a symptom code in place of the confirmed diagnosis, changes the MDC or the DRG. Because this family splits by severity, auditors target CC and MCC capture: each secondary diagnosis must be documented as present, monitored, evaluated or treated during the stay to survive a DRG-validation review. Typical inpatient denial codes for this group: CARC 16 (claim lacks information needed to group the stay), CARC 50 (the admission or procedure is judged not medically necessary), CARC 97 (a service is bundled into the DRG payment).

For teams evaluating QuickIntell software

Evaluate a documentation and coding workflow for DRG 848

Explore QuickCode for qualified coder review and documentation clarification, or QuickScribe for clinician-reviewed visit documentation. Confirm inpatient scope, the supported grouper version and reviewer responsibilities during evaluation. This public reference is not a production grouper and does not determine a claim's reimbursement.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — DRG 848

What is MS-DRG 848?

MS-DRG 848 is "Chemotherapy without Acute Leukemia as Secondary Diagnosis without CC/MCC", a medical Medicare Severity Diagnosis-Related Group in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms). Medicare pays inpatient stays grouped here at the hospital's base rate multiplied by the DRG relative weight.

What is the FY2027 relative weight for DRG 848?

The FY2027 relative weight is 0.7756 (IPPS final rule Table 5, effective October 1, 2026). In FY2026 it was 0.8494, a change of -8.7%.

What is the Medicare base payment for MS-DRG 848?

$5,311.31 for operating costs plus $418.79 for capital, $5,730.10 together, at the FY2027 national rates: weight 0.7756 times the $6,848.00 operating standardized amount and the $539.95 capital rate (IPPS Tables 1A and 1D as corrected by CMS-1849-CN3). DRG 846 (with MCC) comes to $17,326.81 operating on the same basis. DRG 847 (with CC) comes to $9,237.95 operating on the same basis. The hospital's wage index, IME, DSH, outlier and transfer adjustments change what a given stay is paid.

What is the average length of stay for DRG 848?

CMS reports a geometric mean length of stay of 2.6 days and an arithmetic mean of 3.0 days for FY2027. The geometric mean is used for transfer-payment calculations.

Which DRGs are in the same CC/MCC family as 848?

DRG 846 (with MCC, weight 2.5302, GMLOS 5.6 days); DRG 847 (with CC, weight 1.3490, GMLOS 3.7 days). Together with DRG 848 the family spans 0.7756 to 2.5302, a 3.26x spread, so documented complications and comorbidities change payment materially.

What documentation supports the severity level of DRG 848?

DRG 848 is the base-severity assignment: no secondary diagnosis on the CC or MCC lists was coded, or the only ones present are excluded for this principal diagnosis. Revenue-integrity review here looks for undercapture, meaning conditions treated during the stay (electrolyte disorders, specified anemia, acute blood loss, pressure injuries present on admission) that were never documented to the specificity the lists require. A compliant query to the attending, not a coder assumption, is the only way to move a stay to the CC or MCC sibling.

Which codes group to DRG 848?

The v44 Definitions Manual lists 3 principal diagnosis codes for this group. Examples from the principal diagnosis list, Z08 (Encounter for follow-up examination after completed treatment for malignant neoplasm); Z51.11 (Encounter for antineoplastic chemotherapy); Z51.12 (Encounter for antineoplastic immunotherapy).

Is DRG 848 a post-acute transfer DRG?

No. DRG 848 is not on the FY2027 post-acute care transfer list, so the transfer per-diem policy does not apply to it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from the CMS IPPS FY2027 final rule (Table 5) and the v44 ICD-10 MS-DRG Definitions Manual. Relative weights are national factors; actual payment depends on each hospital's wage-adjusted base rate, add-ons, outliers and transfer adjustments. Nothing here is legal, clinical or billing advice; verify grouping against your encoder and the published CMS files.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.